Share-based Payment Arrangement, Expense of Acorda Therapeutics, Inc. from 30 Jun 2010 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acorda Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2010 to 31 Mar 2024.
  • Acorda Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $130,000, a 83% increase year-over-year.
  • Acorda Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $537,000, a 50% decline year-over-year.
  • Acorda Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $478,000, a 68% decline from 2022.
  • Acorda Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,496,000, a 50% decline from 2021.
  • Acorda Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2,995,000, a 63% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Acorda Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $537,000 $130,000 +$59,000 +83% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $478,000 $139,000 -$37,000 -21% 01 Oct 2023 31 Dec 2023 10-K 01 Apr 2024 2023 FY
Q3 2023 $515,000 $140,000 -$224,000 -62% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $739,000 $128,000 -$343,000 -73% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $1,082,000 $71,000 -$414,000 -85% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $1,496,000 $176,000 -$304,000 -63% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $1,800,000 $364,000 -$490,000 -57% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $2,290,000 $471,000 -$483,000 -51% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $2,773,000 $485,000 -$222,000 -31% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,995,000 $480,000 -$1,108,000 -70% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q3 2021 $4,103,000 $854,000 -$1,626,000 -66% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $5,729,000 $954,000 -$1,102,000 -54% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $6,831,000 $707,000 -$1,269,000 -64% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2020 $8,100,000 $1,588,000 -$1,169,000 -42% 01 Oct 2020 31 Dec 2020 10-K 18 Mar 2022 2021 FY
Q3 2020 $9,269,000 $2,480,000 -$812,000 -25% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $10,081,000 $2,056,000 -$2,478,000 -55% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $12,559,000 $1,976,000 -$1,691,000 -46% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $14,250,000 $2,757,000 -$2,216,000 -45% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q3 2019 $16,466,000 $3,292,000 -$1,843,000 -36% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $18,309,000 $4,534,000 -$710,000 -14% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $19,019,000 $3,667,000 -$2,233,000 -38% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $21,252,000 $4,973,000 -$1,641,000 -25% 01 Oct 2018 31 Dec 2018 10-K 28 Feb 2020 2019 FY
Q3 2018 $22,893,000 $5,135,000 -$1,565,000 -23% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $24,458,000 $5,244,000 -$6,456,000 -55% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $30,914,000 $5,900,000 -$1,900,000 -24% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $32,814,000 $6,614,000 -$2,373,000 -26% 01 Oct 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
Q3 2017 $35,187,000 $6,700,000 -$3,300,000 -33% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $38,487,000 $11,700,000 +$2,400,000 +26% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $36,087,000 $7,800,000 -$300,000 -3.7% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $36,387,000 $8,987,000 +$221,000 +2.5% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $36,166,000 $10,000,000 +$1,100,000 +12% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $35,066,000 $9,300,000 +$600,000 +6.9% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $34,466,000 $8,100,000 +$1,000,000 +14% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $33,466,000 $8,766,000 -$14,000 -0.16% 01 Oct 2015 31 Dec 2015 10-K/A 09 Mar 2018 2017 FY
Q3 2015 $33,480,000 $8,900,000 +$1,600,000 +22% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $31,880,000 $8,700,000 +$1,100,000 +14% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $30,780,000 $7,100,000 +$1,343,000 +23% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016 2016 Q1
Q4 2014 $29,437,000 $8,780,000 +$1,541,000 +21% 01 Oct 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
Q3 2014 $27,896,000 $7,300,000 +$800,000 +12% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $27,096,000 $7,600,000 +$1,100,000 +17% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $25,996,000 $5,757,000 +$857,000 +17% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q4 2013 $25,139,000 $7,239,000 +$1,212,000 +20% 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $23,927,000 $6,500,000 +$900,000 +16% 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3
Q2 2013 $23,027,000 $6,500,000 +$900,000 +16% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $22,127,000 $4,900,000 +$709,000 +17% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q4 2012 $21,418,000 $6,027,000 +$524,000 +9.5% 01 Oct 2012 31 Dec 2012 10-K 27 Feb 2015 2014 FY
Q3 2012 $20,894,000 $5,600,000 +$600,000 +12% 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $20,294,000 $5,600,000 +$600,000 +12% 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013 2013 Q2
Q1 2012 $19,694,000 $4,191,000 +$391,000 +10% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1
Q4 2011 $19,303,000 $5,503,000 01 Oct 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
Q3 2011 $5,000,000 +$200,000 +4.2% 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $5,000,000 +$400,000 +8.7% 01 Apr 2011 30 Jun 2011 10-Q 08 Aug 2012 2012 Q2
Q1 2011 $3,800,000 01 Jan 2011 31 Mar 2011 10-Q 09 May 2012 2012 Q1
Q3 2010 $4,800,000 01 Jul 2010 30 Sep 2010 10-Q 07 Nov 2011 2011 Q3
Q2 2010 $4,600,000 01 Apr 2010 30 Jun 2010 10-Q 08 Aug 2011 2011 Q2

Acorda Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $478,000 -$1,018,000 -68% 01 Jan 2023 31 Dec 2023 10-K 01 Apr 2024 2023 FY
2022 $1,496,000 -$1,499,000 -50% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $2,995,000 -$5,105,000 -63% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $8,100,000 -$6,150,000 -43% 01 Jan 2020 31 Dec 2020 10-K 18 Mar 2022 2021 FY
2019 $14,250,000 -$7,002,000 -33% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
2018 $21,252,000 -$11,562,000 -35% 01 Jan 2018 31 Dec 2018 10-K 28 Feb 2020 2019 FY
2017 $32,814,000 -$3,573,000 -9.8% 01 Jan 2017 31 Dec 2017 10-K 28 Feb 2020 2019 FY
2016 $36,387,000 +$2,921,000 +8.7% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $33,466,000 +$4,029,000 +14% 01 Jan 2015 31 Dec 2015 10-K/A 09 Mar 2018 2017 FY
2014 $29,437,000 +$4,298,000 +17% 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
2013 $25,139,000 +$3,721,000 +17% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $21,418,000 +$2,115,000 +11% 01 Jan 2012 31 Dec 2012 10-K 27 Feb 2015 2014 FY
2011 $19,303,000 +$1,526,000 +8.6% 01 Jan 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
2010 $17,777,000 01 Jan 2010 31 Dec 2010 10-K 28 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.